Phase 1/2 study to evaluate the feasibility and tolerability of treatment of previously untreated B-CLL chronic lymphocytic leukemia (B-CLL) patients with recombinant idiotype conjugated to KLH (Id-KLH) [B cell lymphoma vaccine] administered with GM-CSF [granulocyte-macrophage colony-stimulating factors]

Trial Profile

Phase 1/2 study to evaluate the feasibility and tolerability of treatment of previously untreated B-CLL chronic lymphocytic leukemia (B-CLL) patients with recombinant idiotype conjugated to KLH (Id-KLH) [B cell lymphoma vaccine] administered with GM-CSF [granulocyte-macrophage colony-stimulating factors]

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs GTOP 99 (Primary) ; Granulocyte macrophage colony stimulating factor
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genitope Corporation
  • Most Recent Events

    • 01 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top